Abstract

High-Grade Gliomas (HGG) are the most frequent brain tumor in adults. The gold standard of clinical care recommends beginning chemoradiation within 6 weeks of surgery. Disparities in access to healthcare in Argentina are notorious, often leading to treatment delays. We conducted this retrospective study to evaluate if time to chemoradiation after surgery is correlated with progression-free survival (PFS). Our study included clinical cases with a histological diagnosis of Glioblastoma (GBM), Anaplastic Astrocytoma (AA) or High-Grade Glioma (HGG) in patients over 18 years of age from 2014 to 2020. We collected data on clinical presentation, type of resection, time to surgery, time to chemoradiation, location within the Buenos Aires Metropolitan Area (BAMA) and type of health insurance. We found 63 patients that fit our inclusion criteria, including 26 (41.3%) females and 37 (58.7%) males. Their median age was 54 years old (19-86). Maximal safe resection was achieved in 49.2% (n = 31) of the patients, incomplete resection in 34.9% (n = 22) and the other 15.9% (n = 10) received a biopsy, but no resection. The type of health care insurance was almost evenly divided, with 55.6% (n = 35) of the patients having public vs. 44.4% (n = 28) having private health insurance. Median time to chemoradiation after surgery was 8 (CI 6.68-9.9) weeks for the global population. When we ordered the patients PFS by time to chemoradiation we found that there was a statistically significant effect of time to chemoradiation on patient PFS. Patients had a PFS of 10 months (p = 0.014) (CI 6.89-13.10) when they received chemoradiation <5 weeks vs a PFS of 7 months (CI 4.93-9.06) when they received chemoradiation between 5 to 8 weeks and a PFS of 4 months (CI 3.76-4.26 HR 2.18 p = 0.006) when they received chemoradiation >8 weeks after surgery. Also, our univariate and multivariate analysis found that temporal lobe location (p = 0.03), GMB histology (p = 0.02) and biopsy as surgical intervention (p = 0.02) all had a statistically significant effect on patient PFS. Thus, time to chemoradiation is an important factor in patient PFS. Our data show that although an increase in HGG severity contributes to a decrease in patient PFS, there is also a large effect of time to chemoradiation. Our results suggest that we can improve patient PFS by making access to healthcare in Buenos Aires more equitable by reducing the average time to chemoradiation following tumor resection.

Highlights

  • High-grade gliomas (HGG) are the most frequent malignant brain tumors in adults, and tumor recurrence after surgery is almost inevitable [1]

  • The Buenos Aires Metropolitan Area (BAMA) has 14 million people that come from every socioeconomic background [9]

  • Molecular tests for isocitrate dehydrogenase type 1 and 2 (IDH1-2) wild type, MGMT (O6-Methylguanine-DNA methyl transferase) non-methylated, but not 1p/19q co-deletion were included (Fig 1)

Read more

Summary

Introduction

High-grade gliomas (HGG) are the most frequent malignant brain tumors in adults, and tumor recurrence after surgery is almost inevitable [1]. Maximal safe surgical resection is one of the key factors in improving patient outcomes [5]. The Buenos Aires Metropolitan Area (BAMA) has 14 million people that come from every socioeconomic background [9]. The healthcare that patients in the Buenos Aires Metropolitan Area receive depends on their socioeconomic status and where they live [10]. To date there is only one published study that analyzed brain cancer patients’ access to treatment and their outcomes in Argentina [11]. This previous work showed significant differences between public and private institutions throughout the country and the lack of access to specialized brain tumor teams. This study did not assess the impact of access to healthcare on disease progression

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call